Novo Nordisk's Patent Cliff Looms as Analysts Trim Targets and Lilly Steals the Spotlight

Novo Nordisk stock slid after its capital markets day failed to reassure investors, prompting Deutsche Bank, Jefferies and Morgan Stanley to cut targets.

Novo Nordisk's capital markets day was supposed to steady nerves. Instead, it gave the bears more to chew on. Management laid out a long-range ambition of more than DKK 150 billion in risk-adjusted pipeline revenue by 2035, yet the market responded with selling rather than applause. The stock has now surrendered roughly 39% from its 52-week high, changing hands at EUR 33.71 at last count, with a further 0.9% slide to EUR 33.35 in subsequent trading. Since the start of the year, the shares are down 24%. According to media reports, Monday's investor event itself triggered an intraday drop of as much as 9%.

The Danish drugmaker's reassurances that its balance sheet could absorb larger acquisitions did little to quiet the doubters. That DKK 150 billion figure, after all, rests on internally developed, risk-adjusted assets and explicitly excludes any future deals. Investors and analysts alike pressed management on its pricing assumptions and the logic guiding its M&A agenda, and they came away unconvinced.

Sell-Side Cuts Land Within a Day

The analyst community wasted no time adjusting its models. Deutsche Bank slashed its price target to DKK 245 from DKK 265 on Tuesday, keeping its "Sell" rating intact. Jefferies followed suit the same day, trimming its target to DKK 275 from DKK 285 while maintaining a "Hold." The reasoning was consistent across both houses: the capital markets day presentations failed to dispel the uncertainty hanging over the company ahead of semaglutide's patent expiry.

Morgan Stanley added its own weight to the pessimism, downgrading the stock from Equal-weight to Underweight on Monday with a USD 40 price target. The bank cited subdued medium-term growth prospects as its central concern.

The Competitive Noose Tightens

At the heart of every valuation debate sits a single question: how effectively can Novo Nordisk defend its franchise beyond established semaglutide sales? Rival Eli Lilly is making the answer harder by the week. CEO David Ricks said earlier this week that roughly 700,000 seniors have begun treatment since Medicare coverage kicked in during July, with about 70% of them opting for his company's medicines. That is a striking share of a newly opened market.

Competitive pressure in the obesity segment keeps building, and the clock is ticking toward the loss of key semaglutide patents after 2030. Bolt-on acquisitions are meant to plug portfolio gaps and reinforce the internal pipeline, though no concrete transactions have been announced so far.

CagriSema and the Oral Bet Carry the Bull Case

The optimistic scenario rests on the next generation of clinical assets. Fresh Phase 3 data for CagriSema have bolstered its medical credentials. In the REIMAGINE 5 trial, the compound produced an average weight reduction of 12.4% after 60 weeks in adults with type 2 diabetes, versus 9.1% for tirzepatide at the 5-milligram dose. The REDEFINE 9 study showed a 21.0% weight loss after 68 weeks, compared with 2.0% on placebo.

Those results underpin a planned launch of CagriSema for early next year. A standalone version of cagrilintide and a higher-dose CagriSema are slated for 2028, with Zenagamtide to follow later.

Tablets represent the other pillar of the strategy. Doustdar told Reuters on Tuesday that oral medicines could account for half the global obesity market by 2030. Five oral candidates are in development, and manufacturing capacity for such pills is set to be multiplied tenfold. Pull that transformation off, and the company's stated goal of treating more than 60 million patients worldwide by 2030 comes into view. A partnership with technology firm Anthropic, aimed at accelerating drug discovery through software and artificial intelligence, adds another layer to the effort.

China Approval Offers a Rare Bright Spot

Away from the strategic sparring, Novo Nordisk notched an operational win. As Reuters reported, Wegovy received approval in China on 10 September, becoming the first GLP-1 receptor agonist of its class there for treating metabolic dysfunction-associated steatohepatitis (MASH). Whether fresh regional approvals can offset medium-term growth worries remains the pivotal question for the share price. The market wants clear answers on how the company intends to bridge the patent cliff looming over its key active ingredient.

Margin Erosion and Timing Risk

Lurking beneath the pipeline optimism is the real prospect of creeping margin erosion. Failure to hold onto innovation leadership would mean painful market share losses to US competitors, and the company's dependence on obesity and diabetes therapies remains pronounced. Should it keep losing ground on reimbursement from US insurers, those fat margins come under strain. Intensifying competition erodes pricing power, while expanding manufacturing capacity demands substantial investment.

Timing risk compounds the problem. Any delay to CagriSema's launch, or disappointing future trial readouts, narrows the window before semaglutide's patents lapse. If new multi-blockbuster products fail to fill the revenue gap in time, a stretch of stagnant earnings beckons.

What to Watch Next

The coming months will be decisive. As long as the shares can defend their yearly low, there is room for a reassessment of the advanced pipeline. A break below that support, however, would likely leave patent-cliff anxiety and market-share fears in the driver's seat. Investors must now track whether management can stick to the CagriSema timetable. The next major checkpoint is the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan from 28 September to 2 October, where fresh data on the cardiometabolic portfolio should reveal just how sturdy the Danes' scientific foundation really is compared with the competition.